The newly launched European Partnership for Personalised Medicine (EP PerMed) combines European Commission (EC), national and regional funding with the aim of improving future healthcare for all citizens through personalised therapy, diagnosis and prevention.
It has just launched its first Joint Transnational Call 2024 (JTC2024) for research projects that foster the identification or validation of targets for personalised medicine approaches.
The overall objectives of the JTC2024 are to:
- Support research projects aiming at identifying or validating targets for personalised medicine approaches in combination with development of companion biomarkers or other markers to allow for monitoring of treatment outcomes and patient stratification
- Encourage and enable interdisciplinary collaborations by combining pre-clinical and clinical research in translational projects, and multi-actor research by engaging a range of other relevant disciplines such as bioinformatics/health informatics/data research, ELSI research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to empower the implementation of PM
- Encourage cross-sectorial collaborations, by including academia, health care providers, the private sector (e.g., SMEs, small and medium-sized enterprises), industry, as well as regulatory/HTA agencies and patient organisations
Consortiums are expected to be collaborative, interdisciplinary, transnational and trans-sectional, and research projects in all disease areas are encouraged.
This Call has an available budget of €40 million, and all stakeholders are invited to take part in the calls. A partnering tool developed and supported by the EP PerMed will also be available in 2024
There will be an open information day introducing JTC2024 to prospective applicants coming shortly.
Further Details
All Calls will be announced on the EP PerMed website: https://www.eppermed.eu/